Your browser doesn't support javascript.
loading
Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial.
de Fijter, J W; Holdaas, H; Øyen, O; Sanders, J-S; Sundar, S; Bemelman, F J; Sommerer, C; Pascual, J; Avihingsanon, Y; Pongskul, C; Oppenheimer, F; Toselli, L; Russ, G; Wang, Z; Lopez, P; Kochuparampil, J; Cruzado, J M; van der Giet, M.
Afiliación
  • de Fijter JW; Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands.
  • Holdaas H; Section of Nephrology, Department of Transplant Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Øyen O; Section of Transplant Surgery, Department of Transplant Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Sanders JS; Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Sundar S; Department of Nephrology, Columbia Asia Hospitals, Malleshwaram West, Bangalore, India.
  • Bemelman FJ; Department of Nephrology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
  • Sommerer C; Department of Nephrology, Heidelberg University Hospital, Heidelberg, Germany.
  • Pascual J; Department of Nephrology, Hospital del Mar, Barcelona, Spain.
  • Avihingsanon Y; Faculty of Medicine, Chulalongkorn University and Excellent Center of Organ Transplantation, King Chulalongkorn Memorial Hospital, Patumwan, Bangkok, Thailand.
  • Pongskul C; Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
  • Oppenheimer F; Department of Nephrology and Kidney Transplantation, Hospital Clínic de Barcelona, Barcelona, Spain.
  • Toselli L; Kidney, Liver and Pancreas Transplant Unit, CRAI Norte, Ministry of Health, Buenos Aires, Argentina.
  • Russ G; University of Adelaide and Central and Northern Adelaide Renal and Transplant Service, Royal Adelaide Hospital, North Terrace, Adelaide, Australia.
  • Wang Z; Biometrics and Statistical Science, Novartis Pharmaceuticals, East Hanover, NJ.
  • Lopez P; Research and Development, Novartis Pharma AG, Basel, Switzerland.
  • Kochuparampil J; Research and Development, Novartis Pharma AG, Basel, Switzerland.
  • Cruzado JM; Department of Nephrology, University Hospital of Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
  • van der Giet M; Department of Nephrology, Charité - Universitätsmedizin, Berlin, Germany.
Am J Transplant ; 17(7): 1853-1867, 2017 07.
Article en En | MEDLINE | ID: mdl-28027625
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Riñón / Tacrolimus / Everolimus / Rechazo de Injerto / Inmunosupresores Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Am J Transplant Asunto de la revista: TRANSPLANTE Año: 2017 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Riñón / Tacrolimus / Everolimus / Rechazo de Injerto / Inmunosupresores Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Am J Transplant Asunto de la revista: TRANSPLANTE Año: 2017 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos